We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 28, 2020

Liraglutide Downregulates Circulating Proglucagon-Derived Peptides, Improving Body Weight, Insulin Secretion, and Action

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Effect of Liraglutide Versus Placebo Treatment on Circulating Proglucagon-Derived Peptides That Mediate Improvements in Body Weight, Insulin Secretion and Action: A Randomized Controlled Trial
Diabetes Obes Metab 2020 Nov 02;[EPub Ahead of Print], SH Kim, F Abbasi, C Nachmanoff, K Stefanakis, A Kumar, B Kalra, G Savjani, CS Mantzoros

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading